Hyperbaric oxygen and radiation therapy: a review

Fernández, E.; Morillo, V.; Salvador, M.; Santafé, A.; Beato, Inmaculada; Rodríguez, M.; Ferrer, C.

doi:10.1007/s12094-020-02513-5

Cited by 26 publications

(17 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-6 is derived from Th2 cells and presents abnormal changes in inflammatory responses [ 16 ]. IFN- γ is secreted by Th1 cells, which can recognize tumor cells and inhibit the proliferation of tumor cells and tumor angiogenesis [ 17 ]. Related research pointed out [ 18 ] that radiotherapy and chemotherapy can inhibit the immune function of the body, with the most obvious change detected in T lymphocytes, of which the main clinical manifestations are the reduction of CD3+, CD4+, and CD4+/CD8+.…”

Section: Discussionmentioning

confidence: 99%

Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function

Liu

Sun

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Objective. To assess the efficacy of three-dimensional conformal radiotherapy (3D-CRT) combined with GT chemotherapy (gemcitabine+docetaxel) in the treatment of advanced bladder cancer and its influence on inflammatory factors and immune function. Methods. A total of 42 elderly patients with advanced bladder cancer who were admitted to our hospital from January 2019 to January 2020 were included and assigned to the GT group (21 cases) receiving GT chemotherapy and combination group (21 cases) given 3D-CRT combined with GT chemotherapy. The clinical efficacy, immune function, inflammatory factors, tumor markers, urinary angiogenesis molecules before and after treatment, 1-year survival rate, 2-year survival rate, and incidence of adverse reactions of the two groups were compared. SPSS 22.0 statistical software was used for data processing and analysis. Results. The combination group had 5 cases of CR, 12 cases of PR, 3 cases of SD, and 1 case of PD, with an ORR of 80.95% (17/21), which was remarkably higher than the ORR of 57.14% (12/21) in the GT group which had 3 cases of CR, 9 cases of PR, 5 cases of SD, and 4 cases of PD ( P < 0.05 ). The 1-year survival rate of the combination group was 76.19% (16/21), and the 2-year survival rate was 47.62% (10/21), which were higher than the 1-year survival rate of 47.62% (10/21) and 2-year survival rate of 19.05% (4/21) in the GT group ( P < 0.05 ). The two groups presented similar results in terms of adverse reactions rate ( P > 0.05 ). After treatment, the combination group obtained significantly lower levels of urinary bladder cancer antigen (UBC), nuclear matrix protein-22 (NMP-22), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) than the GT group ( P < 0.05 ). The CD3+, CD4+, and CD4+/CD8+ levels of the two groups of patients were lower than those before treatment ( P < 0.05 ), but no statistical difference was observed between the two groups after treatment ( P > 0.05 ). The levels of interleukin-6 (IL-6) and interferon-γ (IFN-γ) of the two groups witnessed a decline after treatment, with lower results in the combination group as compared to the control group ( P < 0.05 ). Before treatment, no significant difference in the Generic Quality of Life Inventory-74 (GQOLI-74) score between the two groups was found ( P > 0.05 ). After treatment, the combination group had higher GQOLI-74 scores than the GT group ( P < 0.05 ). Conclusion. 3D-CRT combined with GT chemotherapy yields a significant effect on the treatment of elderly advanced bladder cancer by effectively protecting immune function, mitigating inflammation, inhibiting tumor marker levels and the expression of angiogenic molecules, and improving patients’ survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function

Liu

Sun

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Among these are the primary surgical technique performed with marginal mandibulectomy in the jawbone that would later be irradiated, with a dose greater than 50 Gy, and the placement of dental implants in the perioperative time during the reconstructive microsurgery. Although there is still no consensus in the literature about the better time for dental implants to be placed after RT, the recommendation has been to wait for intervals of 6-12 months after RT [9,10].…”

Section: Discussionmentioning

confidence: 99%

Refractory advanced osteoradionecrosis (ORN) in the mandible: Analysis of predictive factors, clinical, imaging, and therapeutic characteristics

Bernaola-Paredes

Filippetti

Ramos

et al. 2022

Int J Case Rep Images

View full text Add to dashboard Cite

Introduction: Osteoradionecrosis (ORN) of the jaws is a late, severe and difficult to manage side effect in patients who underwent radiotherapy (RT) in the head and neck region. Treatment remains controversial, especially in refractory cases that do not respond to multiple attempts with different therapies, due to their complex pathophysiology. It is based on conservative non-surgical approaches, even in large resections using free flaps. The present study aims to present and describe a clinical case of refractory ORN treated through microsurgical reconstruction and adjuvant therapies. Case Report: A 51-year-old female patient with oncological background of oral squamous cell carcinoma (OSCC) of the floor of the mouth, previously treated with marginal mandibulectomy, and who subsequently relapsed. In a second surgical time, left hemimandibulectomy was performed, followed by microsurgical reconstruction with the fibular osteomusculocutaneous free flap, besides, dental implants were placed in the perioperative time. Radiotherapy was performed using a 3D conformal technique technique with a total dose of 66 Gy and after six months the patient developed infection in the treated region and it was observed partial exposure of the fibular flap and intra and extraoral purulent drainage, and after imaging analysis the diagnosis of ORN was established. Some non-surgical therapeutic attempts were performed without clinical response and a new surgical approach was performed based on sequestrectomy, the removal of the titanium plaque and dental implants with a second microsurgical reconstruction with forearm fasciocutaneous free flap to cover the soft tissue defect was done. Conclusion: The pathophysiology of ORN remains controversial and the predictive factors for its appearance, development, and progression are still unclear. Marginal mandibulectomy could be associated with a rapid onset of ORN in patients submitted to adjuvant RT and it could be considered as a potential predictive factor. Combined therapies are reliable alternatives for local control in refractory cases and in advanced stages, and surgical removal with microsurgical reconstruction procedures are still a feasible alternative that has shown satisfactory clinical results.

show abstract

“…HBOT has been used to treat late-onset RT-related injuries since 1975 (52), being CNS lesions a type 3 recommendation. In 1953, Gray et al postulated that the primary source of radioresistance was oxygen deficiency (53).…”

Section: Hyperbaric Oxygen Therapy As a Hypoxia Reverser Treatmentmentioning

confidence: 99%

Hyperbaric Oxygen Therapy as a Complementary Treatment in Glioblastoma—A Scoping Review

et al. 2022

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults. The mainstay of management for GBM is surgical resection, radiation (RT), and chemotherapy (CT). Even with optimized multimodal treatment, GBM has a high recurrence and poor survival rates ranging from 12 to 24 months in most patients. Recently, relevant advances in understanding GBM pathophysiology have opened new avenues for therapies for recurrent and newly diagnosed diseases. GBM's hypoxic microenvironment has been shown to be highly associated with aggressive biology and resistance to RT and CT. Hyperbaric oxygen therapy (HBOT) may increase anticancer therapy sensitivity by increasing oxygen tension within the hypoxic regions of the neoplastic tissue. Previous data have investigated HBOT in combination with cytostatic compounds, with an improvement of neoplastic tissue oxygenation, inhibition of HIF-1α activity, and a significant reduction in the proliferation of GBM cells. The biological effect of ionizing radiation has been reported to be higher when it is delivered under well-oxygenated rather than anoxic conditions. Several hypoxia-targeting strategies reported that HBOT showed the most significant effect that could potentially improve RT outcomes, with higher response rates and survival and no serious adverse events. However, further prospective and randomized studies are necessary to validate HBOT's effectiveness in the ‘real world' GBM clinical practice.

show abstract

Hyperbaric oxygen and radiation therapy: a review

Cited by 26 publications

References 29 publications

Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function

Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function

Refractory advanced osteoradionecrosis (ORN) in the mandible: Analysis of predictive factors, clinical, imaging, and therapeutic characteristics

Hyperbaric Oxygen Therapy as a Complementary Treatment in Glioblastoma—A Scoping Review

Contact Info

Product

Resources

About